Pharming Group Presents New Leniolisib Pediatric and CVID Data at CIS 2026 Annual Meeting
Summary
Pharming Group announced presentations at the CIS 2026 Annual Meeting, sharing new pediatric data for leniolisib in APDS and clinical experience in CVID and related disorders, supporting ongoing trials.
Key Events
-
New Leniolisib Clinical Data Presented
Pharming Group presented interim safety and efficacy outcomes from a long-term extension study of leniolisib in pediatric APDS patients (4-11 years) and clinical experience data for leniolisib in CVID and CVID-like disorders at the CIS 2026 Annual Meeting.
-
Supports Ongoing Phase II Trials
The clinical observations from expanded access use support two ongoing Phase II clinical trials evaluating leniolisib in CVID and other primary immunodeficiencies with immune dysregulation, with results expected in H2 2026.
-
Expands Understanding of APDS and PIDs
The presentations advance the understanding of Activated PI3Kδ Syndrome (APDS) and other primary immunodeficiencies characterized by immune dysregulation, potentially broadening leniolisib's therapeutic scope.
Analysis
Pharming Group's presentations at the Clinical Immunology Society (CIS) Annual Meeting provide new clinical insights into leniolisib, an already approved drug for APDS. The interim pediatric data for APDS and expanded access use in CVID and CVID-like disorders suggest potential for label expansion and broader application. These findings support ongoing Phase II trials, with results anticipated in the second half of 2026, which could further enhance the drug's market potential.
At the time of this filing, PHAR was trading at $13.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $8.39 to $21.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.